Izikom Mita

Izicom Mite: antiparkinsonian drug with the active substance Levodopa + Carbidopa

Izicom Mite is an antiparkinsonian drug produced by the German company Isis Pharma GmbH. The main components of the drug are Levodopa and Carbidopa, which in combination provide effective therapy for Parkinson's disease and symptomatic parkinsonism.

Izicom Mite is presented in the form of tablets, each of which contains 100 mg of active ingredients. The drug has several synonyms, such as Dopar 275, Duellin, Zymox, Carbidopa and Levodopa - Teva, Nakom, Sindopa, Sindopa 110, Sindopa 275, Sinemet, Sinemet SR, Tidomet LS, Tidomet plus, Tidomet forte, Tremonorm.

Izicom Mite is effective in the treatment of Parkinson's disease, which is a chronic disease of the nervous system manifested in the form of tremors, muscle weakness, loss of coordination and other symptoms. The drug is also used for the symptomatic treatment of parkinsonism caused by other causes.

Despite its effectiveness, Izikom Mite has a number of contraindications and side effects that must be taken into account when prescribing the drug. Contraindications include severe atherosclerosis, hypertension, liver, kidney, blood diseases, glaucoma, melanoma, bronchial asthma, mental illness, uncompensated pathology of the cardiovascular, respiratory and endocrine systems.

Among the side effects of Izikom Mite, choreoathetoid hyperkinesis, arrhythmias, psychotic and paranoid reactions, dyspepsia, dizziness, visual impairment, hemolytic anemia, agranulocytosis, leukopenia, alopecia, allergic reactions and ulceration of the gastrointestinal tract may occur.

Interaction of Izik Mite with other drugs can also cause serious consequences. For example, the drug may weaken the effect of vitamin B6 and enhance the effect of MAO inhibitors.

An overdose of Izik Mite can lead to serious consequences, such as muscle twitching, convulsive closing of the eyelid, nausea, vomiting, diarrhea, irregular and rapid pulse, loss of consciousness, convulsions, anxious agitation, hallucinations and other mental disorders.

When prescribing Izicom Mite, it is necessary to take into account the individual characteristics of the patient, his age, state of health and the presence of other diseases. It is not recommended to use the drug without consulting a doctor.

In general, Izicom Mite is an effective antiparkinsonian drug, but its use should be limited only to a neurologist and in compliance with all recommendations and warnings.